A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
This study is investigating a new tablet called Venglustat for people aged 16 and older who have Fabry disease. The main goal is to see if Venglustat can ease nerve pain in the arms and legs, and tummy pain, compared to a placebo (a dummy tablet with no medicine). We are looking for people who haven't been treated for Fabry disease for at least six months, or who have never been treated before. Participants will take either Venglustat or the placebo for 12 months. After this, everyone will have the chance to take Venglustat in an open-label extension part of the study. Regular check-ups will happen about every three months to see how you are doing.
Em resumo
Sobre o que é este estudo?
This study is focusing on Fabry disease, a rare genetic condition that can cause various health problems, including significant pain. Specifically, we are looking at nerve pain in the arms and legs (neuropathic pain) and tummy pain (abdominal pain).
We are testing a new medicine called Venglustat, which comes in tablet form. The main purpose of this research is to find out if Venglustat can help reduce these painful symptoms in people with Fabry disease. We compare it to a 'placebo', which looks exactly like the study medicine but doesn't contain any active drug. This helps us understand if the new medicine is truly effective.
This is a 'Phase 3' study, which means it's one of the final steps before a new medicine might become widely available. Doctors and scientists are hopeful that Venglustat could offer a new way to manage these challenging pain symptoms for people living with Fabry disease.
Pontos principais
- Tests a new tablet (Venglustat) for Fabry disease pain.
- Compares Venglustat to a dummy tablet (placebo) first.
- Open to people aged 16+ who haven't recently been treated for Fabry.
- Involves regular check-ups (every 3 months) for up to 4 years.
- Você pode parar de participar a qualquer momento.
- Your health will be closely monitored throughout.
Quem pode ser elegível?
You might be able to join this study if you are 16 years old or older and have a confirmed diagnosis of Fabry disease with symptoms. We are looking for people who haven't received treatment for Fabry disease in the last six months, or who have never been treated for it before. A key part of joining is having an average pain score of 3 or more (on a scale of 0 to 10, where 10 is the worst pain imaginable) for either nerve pain in your arms or legs, or tummy pain.
However, there are reasons why you might not be able to take part. For example, if you have certain other serious health conditions like a recent heart attack, stroke, or uncontrolled high blood pressure. You also wouldn't be able to join if you have certain infections like Hepatitis C, HIV, or Hepatitis B, or if your pain is known to be caused by something other than Fabry disease.
If you're thinking about joining, it's important that you or your partner (if you are a man) are using effective birth control methods, and women should not be pregnant or breastfeeding. We also need to check your kidney function and other health markers to make sure it's safe for you to take part.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 16 anos ou mais?
- Do you have a diagnosis of Fabry disease with symptoms?
- Have you not received Fabry disease treatment for at least the past 6 months (or ever)?
- Do you experience nerve pain in your arms/legs or tummy pain, scoring 3 or more out of 10?
- Are you able to use effective birth control if required?
- Do you generally have good health apart from your Fabry disease?
O que envolve a participação?
If you decide to join, the study will have two main parts. For the first 12 months, you will take either the study medicine (Venglustat) or a dummy tablet (placebo). Neither you nor your study doctor will know which one you are taking – this is called 'double-blind'. During this time, you'll have study visits about every three months to check on your health and how you're feeling.
After these 12 months, if you wish to continue and have completed the first part, you will enter an 'open-label' period. This means everyone will receive Venglustat, and both you and your doctor will know you're taking the active medicine. This part could last for another 12 months, or potentially longer, until all participants finish the study at the same time. The total time you could be in the study, including initial checks and follow-up, could be up to about 46 months (nearly 4 years). Throughout, there will be regular checks to make sure you are safe and that the medicine is well tolerated.
Riscos e benefícios potenciais
Locations (50)
- University of Alabama -The Kirklin Clinic- Site Number : 8400011Código postal verificadoBirmingham, Estados Unidos
- David Geffen School of Medicine at UCLA- Site Number : 8400006Código postal verificadoLos Angeles, Estados Unidos
- University of California Irvine Medical Center- Site Number : 8400019Código postal verificadoOrange, Estados Unidos
- AdventHealth Orlando- Site Number : 8400008Código postal verificadoOrlando, Estados Unidos
- Emory University School of Medicine - Atlanta- Site Number : 8400010Código postal verificadoAtlanta, Estados Unidos
- WMCHealth Advanced Physician Services- Site Number : 8400001Código postal verificadoHawthorne, United States
- Cincinnati Children's Hospital Medical Center- Site Number : 8400013Código postal verificadoCincinnati, Estados Unidos
- UPMC Montefiore- Site Number : 8400009Código postal verificadoPittsburgh, Estados Unidos
- Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012Código postal verificadoDallas, Estados Unidos
- University of Utah Health Hospital- Site Number : 8400005Código postal verificadoSalt Lake City, United States
- Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004Código postal verificadoFairfax, United States
- Investigational Site Number : 0320001Código postal verificadoPergamino, Argentina
Perguntas frequentes
What is Fabry disease?
Fabry disease is a rare genetic condition that can affect many parts of the body, including the nerves, kidneys, and heart, often causing pain and other symptoms.
What does 'placebo' mean?
A placebo is a dummy tablet that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the new medicine's effects.
Quanto tempo estarei no estudo?
The first main part of the study is 12 months. If you continue, the study could last up to about 46 months (nearly 4 years) in total.
Will I know if I'm getting the active medicine?
For the first 12 months, neither you nor your doctor will know if you're taking Venglustat or the placebo. After that, if you continue, you will know you are taking Venglustat.
What kind of pain is the study looking at?
This study is focused on nerve pain in the arms and legs, and tummy pain, that is related to your Fabry disease.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.